Views: 18 Author: Site Editor Publish Time: 2026-04-21 Origin: Site
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, accounting for an estimated 17.9 million deaths annually, representing approximately 32% of all global deaths, according to the World Health Organization. Early detection is critical to reducing morbidity and mortality, yet traditional laboratory-based diagnostics often delay timely decision-making.
Point-of-care testing (POCT) devices are transforming the landscape of cardiovascular screening by enabling rapid, accurate, and decentralized diagnostics. This article explores the clinical value, key biomarkers, and real-world applications of POCT in early cardiovascular disease screening.
CVDs—including coronary artery disease, heart failure, and acute myocardial infarction—often develop silently over years. Early-stage detection allows for:
Timely risk stratification
Preventive interventions
Reduced hospitalization rates
Improved long-term outcomes
However, conventional diagnostic workflows rely on centralized laboratories, leading to delays ranging from hours to days. In acute settings, such delays can be life-threatening.
POCT refers to diagnostic testing performed at or near the site of patient care, delivering results within minutes rather than hours. Modern POCT platforms integrate:
Compact instrumentation
User-friendly interfaces
Minimal sample preparation
Rapid turnaround time (typically 5–20 minutes)
These features make POCT particularly valuable in emergency departments, outpatient clinics, ambulances, and even home-based care.
POCT devices are widely used to measure critical cardiovascular biomarkers associated with early disease detection and acute events:
Cardiac troponins are the gold standard for detecting myocardial injury.
Elevated troponin levels indicate myocardial infarction
High-sensitivity assays enable detection within 2–3 hours of symptom onset
Recommended by the European Society of Cardiology for early rule-in/rule-out strategies
These biomarkers are essential for heart failure screening and prognosis.
BNP levels correlate with cardiac wall stress
POCT BNP testing has demonstrated diagnostic accuracy comparable to central lab testing
According to the American Heart Association, BNP testing improves diagnostic confidence in suspected heart failure cases
Although not specific to CVD, D-dimer is valuable in excluding thromboembolic events such as pulmonary embolism.
Rapid POCT D-dimer testing supports early triage decisions
Reduces unnecessary imaging procedures
High-sensitivity CRP is used to assess inflammation and cardiovascular risk.
Elevated hs-CRP is associated with increased risk of atherosclerosis
Recommended for risk stratification in intermediate-risk patients
POCT significantly shortens the time to diagnosis. Studies show that POCT-based troponin testing can reduce door-to-decision time by up to 60% in emergency settings (Source: National Institutes of Health).
Early diagnosis enables:
Faster initiation of treatment
Reduced complication rates
Lower mortality in acute coronary syndromes
POCT devices bring diagnostics closer to patients, especially in:
Rural or resource-limited settings
Primary care clinics
Mobile healthcare units
By reducing hospital admissions and unnecessary diagnostic procedures, POCT contributes to overall healthcare cost savings.
Rapid POCT cardiac marker testing allows clinicians to quickly rule in or rule out myocardial infarction, improving patient flow and reducing overcrowding.
General practitioners can use POCT devices for early risk screening, enabling proactive management of high-risk patients.
POCT enables early diagnosis even before hospital arrival, allowing pre-hospital triage and activation of cardiac care pathways.
POCT bridges the gap where access to centralized laboratories is limited, supporting equitable healthcare delivery.
Advancements in POCT technology are expected to further enhance cardiovascular screening:
Integration with digital health platforms and AI
Multiplex testing capabilities (simultaneous detection of multiple biomarkers)
Improved sensitivity and specificity comparable to laboratory analyzers
These innovations will continue to drive the shift toward personalized and preventive cardiovascular care.
As the demand for rapid and reliable cardiovascular diagnostics continues to grow, innovative POCT technologies are becoming essential tools in modern healthcare systems. Medlere addresses this need with its advanced POCT platforms, including the FiCA Immunofluorescence Analyzer and the UClia POCT Chemiluminescence system.
The FiCA series is designed for fast and efficient quantitative detection of key cardiac biomarkers such as troponin, BNP, and D-dimer, making it highly suitable for emergency departments, outpatient clinics, and decentralized laboratories. With its compact design, user-friendly operation, and broad test menu, FiCA enables clinicians to obtain accurate results within minutes, supporting timely clinical decision-making.
Meanwhile, the UClia system leverages chemiluminescence technology to deliver enhanced sensitivity and precision, meeting the growing demand for high-performance POCT in cardiovascular and critical care settings. Its capability to provide laboratory-level accuracy in a point-of-care format makes it an ideal solution for institutions seeking to balance speed and analytical performance.
By integrating speed, accuracy, and flexibility, Medlere’s POCT solutions empower healthcare providers to advance early cardiovascular screening, improve patient outcomes, and move closer to a more proactive and accessible model of care.
World Health Organization. Cardiovascular diseases (CVDs) fact sheet.
European Society of Cardiology. Guidelines for the management of acute coronary syndromes.
American Heart Association. Heart failure biomarker recommendations.
National Institutes of Health. Impact of POCT on emergency care workflows.
